SUPPLY CHAIN RESOURCE COOPERATIVE

Category Archives: Pharmaceutical Supply Chain

  1. I had the opportunity to hear Ken Frazier, CEO of Merck,  speak at the SC50 meeting.   Ken was a single child raised by a single father in Philadelphia, making his way into Harvard Law eventually.  Prior to becoming CEO, Ken was the general counsel for Merck, and was the lead representative in defending Merck against […]

    [No comments]

  2. This week the Supply Chain Resource Cooperative is holding an executive panel focused on the challenges of dealing with counterfeiting in the supply chain.  We will be hosting a number of major public and private sector participants including the Air Force, the Treasury, the pharmaceutical sector, consumer products sector, technology sector, and services sector.  All of these […]

    [1 comment]

  3. I spent the day at Biogen’s headquarters in Cambridge, MA today, with a group of executives sharing ideas on how to drive innovation.  Biogen is already a highly innovative company, as they have continued to drive new treatments in MS, and in 2014, the first major treatment advances in nearly two decades for people living with […]

    [2 comments]

  4. Joydeep Ganguly from Biogen Idec spoke in my Supply Chain Relationships class last week, and shared his insights on how Biogen’s supply chain evolved.  Since graduating from the NC State Jenkins MBA program in 2006, Joydeep Ganguly has risen through the ranks at Biogen Idec – the world’s oldest independent biotechnology company and the largest […]

    [No comments]

  5. NC State kicked off classes last week, and as usual our incoming group of MBA students were lined up with projects as part of their entry class into supply chain management, MBA 541.  I have been teaching this class, called Supply Chain Relationships, for the last 15 years at NC State. This class develops major […]

    [No comments]

  6. As “Obamacare” continues to plow forward, the effects on the healthcare environment are slowly but surely being felt.  One of the biggest recipients of this trend is the pharmaceutical environment. Several trends have shaped the pharmaceutical ecosystem in the last few years, and Obamacare is only one among many.  The issues supply chain executives face […]

    [No comments]

  7. Although strategic sourcing capabilities are well established in industries ranging from automotive to electronics, they are still in the formative stages in the biotechnology sector.   It isn’t easy to drive change in biotech companies for a number of reasons. With their external spend increasing so fast, there is great pressure on biotech companies to rethink […]

    [1 comment]

  8. My new book comes out this month, which focuses on the biopharma supply chain and the numerous trends and challenges that exist today, and which will continue to occur down the road.. Titled “Distribution, Regulatory, Systems, and Structural Changes in Biopharmaceutical Supply Chain”, the book covers the major themes and changes in the biopharmaceutical supply […]

    [No comments]

  9. At a recent conference held by Tracelink (Nexus Conference, New Brunswick, NJ, Septmber 2011), Bob Celeste from the GS1 organization shared his views on how the new era of visibility in the healthcare landscape is evolving. Visibility is a term which comprises the entire space including subsets defined as Track & Trace/Traceability. This term can […]

    [3 comments]

  10. Over the last eight years, I’ve had the opportunity to meet with many different participants in the healthcare supply chain: drug manufacturers, Group Purchasing Organizations, retail pharmacies, hospital pharmacies, physicians, consultants, academics, clinical researchers, third party logistics providers, pharmacy benefits managers, and others. Over this period, the level of anxiety has been mounting considerably, culminating […]

    [2 comments]